Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.79 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.76 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.76 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.76 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21408904 | 1.00 | GPBAR1 (0.79) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL15292874 | 1.00 | GPBAR1 (0.79) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL15292879 | 1.00 | GPBAR1 (0.79) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL25926256 | 0.89 | GPBAR1 (0.76) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL25926254 | 0.89 | GPBAR1 (0.76) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL22722196 | 0.89 | GPBAR1 (0.94) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL22572510 | 0.89 | GPBAR1 (0.94) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL22572519 | 0.89 | GPBAR1 (0.94) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL22572524 | 0.89 | GPBAR1 (0.94) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL24712916 | 0.89 | GPBAR1 (1.00) | GPBAR1NR1H4MEN1KMT2AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2022-07-14 | — | — | US | claimed |
| US-20210148933-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2021-05-20 | — | — | US | claimed |
| EP-3773919-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2021-02-17 | — | — | EP | claimed |
| WO-2019186141-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2019-10-03 | — | — | WO | claimed |
| CN-119000956-A | Kit for simultaneously detecting 15 bile acid spectrums and 3 bile acid precursors in serum and detection method | 上海捷易生物科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12084704-B2 | Methods for producing isobutene from 3-methylcrotonic acid | GLOBAL BIOENERGIES (FR) | 2024-09-10 | — | — | US | disclosed |
| EP-3622080-B1 | IMPROVED METHODS FOR PRODUCING ISOBUTENE FROM 3-METHYLCROTONIC ACID | GLOBAL BIOENERGIES (FR) | 2024-03-27 | — | — | EP | disclosed |
| US-20210148933-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2021-05-20 | — | — | US | disclosed |
| EP-3773919-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019186141-A1 | METHODS AND ASSAYS FOR USE IN DIAGNOSIS OF LAMINITIS | Pepsis Limited (GB) | 2019-10-03 | — | — | WO | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| US-20120191434-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR MODELING CHINESE HAMSTER OVARY (CHO) CELL METABOLISM | GT LIFE SCIENCES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-1497247-A2 | MIMICS OF ACYL COENZYME-A, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1495034-A2 | MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087108-A2 | MIMICS OF ACYL COENZYME-A, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087040-A2 | MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | PLAT, PLG, PLAUR | GPBAR1 3709/4885NR1H4 3171/4885MEN1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.